Almirall, S.A. (0O9B.L)
| Previous close | 10.34 |
| Open | 10.30 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 10.30 - 10.30 |
| 52-week range | 8.11 - 11.29 |
| Volume | |
| Avg. volume | 48,403 |
| Market cap | 1.807B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.28 |
| Earnings date | 22 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Almirall And Two Additional Stocks Considered Below Estimated Market Value
Amidst a complex landscape where global markets display mixed signals, investors are increasingly turning their attention to value and small-cap stocks. This shift comes as major indices like the Dow Jones Industrial Average see notable performance, highlighting a growing divergence from growth stocks which have recently underperformed. In such an environment, identifying undervalued stocks becomes crucial. These are shares that trade below what they are fundamentally worth, offering...
Business WireAlmirall’s H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics Sales
BARCELONA, Spain, July 22, 2024--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced its financial results from the first half of 2024. Almirall continued to deliver strong sales growth in the second quarter of 2024 which was mainly driven by the dermatology business in Europe. Total Net Sales increased by 6.7% to a total of €497.2 MM, EBITDA was €104.5 MM (increase of 3.2% YoY) driven by higher sales growth, with a gross margin of 65,1%. Dermatology sales
GlobeNewswireEloxx Pharmaceuticals Provides Pipeline and Financing Updates
First two subjects dosed in Phase 1 clinical trial of ZKN-013; ZKN-013 is being developed for the potential treatment of rare dermatological and other diseases associated with nonsense mutations Positive written FDA feedback and guidance from a pre-Investigational New Drug Application (PIND) meeting provides pathway to IND application submission to initiate a Phase 2 clinical trial in the US with ELX-02 in patients with nonsense mutation alport syndrome (NMAS) Secured binding commitment for addi
